NovaVision researches and aims to develop and provide scientifically based, neurostimulation medical devices and technologies to non-invasively restore the vision of patients with neurological visual loss. The firm was founded in 1998 and is based in Boca Raton, Florida.
NovaVision has filed 13 patents.
Cerebral cortex, Visual system, Cerebrum, Vision, Brodmann areas
Cerebral cortex, Visual system, Cerebrum, Vision, Brodmann areas
Latest NovaVision News
Aug 30, 2022
Concurrent with the transaction, Bill Schoenherr has been promoted to president of NovaVision while longtime president Mike Messmer is retiring. Email address I accept: Email address A link has been emailed to you - check your inbox. Sign in to your account Email address Nearly there! We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there. If you do not receive this within five minutes, please try and sign in again. If the problem persists, please email: firstname.lastname@example.org. Copyright PEI Media Share with other subscribers Cancel
NovaVision Frequently Asked Questions (FAQ)
When was NovaVision founded?
NovaVision was founded in 1998.
Where is NovaVision's headquarters?
NovaVision's headquarters is located at 951 Broken Sound Parkway, Boca Raton.
What is NovaVision's latest funding round?
NovaVision's latest funding round is Unattributed VC.
How much did NovaVision raise?
NovaVision raised a total of $41M.
Who are the investors of NovaVision?
Investors of NovaVision include Crossbow Ventures, Noro-Moseley Partners, Tullis Health Investors, Oakwood Medical Investors, Chicago Growth Partners and 4 more.
Who are NovaVision's competitors?
Competitors of NovaVision include Pixium and 4 more.
Compare NovaVision to Competitors
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
Mercator MedSystems is a medical technology company that focuses on the treatment of peripheral artery disease. The company offers catheter-guided, microfluid injection systems for site-specific, non-systemic delivery of therapeutic agents directly across any blood vessel, providing efficient and targeted treatment for vascular diseases. The technology also finds application in the treatment of hypertension, oncology, and regenerative medicine. Mercator MedSystems was formerly known as EndoBionics. It was founded in 1999 and is based in Emeryville, California.
Actuality Medical develops systems for improving the precision, morbidity, and quality of radiation oncology and surgical excision for soft tissue indications - initially for prostate and breast cancer. The company's first product, PerspectaSeed 4D, will apply intra-operative dynamic dosing - "continuous GPS" - to prostate brachytherapy. It is designed to reduce hot spots and cold spots by continually monitoring the actual positions of placed seeds and recommending placements for subsequent seeds.
technology for real-time monitoring of the metabolic state of the patient and as a endpoint of resuscitationn nCritisense's first generation product - the "CritiView" is an patient monitoring system providing real-time continuous information via four physiological parameters, sensed at the tissue level, reflecting the systemic metabolic state. nCritiView is the only device providing continuous, real-time multi-parametric physiological data at the tissue and cellular level, by monitoring the mitochondrial function and the microcirculatory blood flow and oxygen saturation.n
Metamodal is a company that received a SBIR Phase I grant for a project entitled: Viability of a Sensory Substitution Device Giving Blind Users Sight Through Sound. Their project aims to determine the commercial viability of a sensory substitution device that enables blind users to "see with sound" by transforming images from a wearable camera into sounds. One aspect to be investigated is whether or not the proposed device is useful and effective in the daily life of blind users. Another aspect is to determine the ease with which blind users can learn to interpret the sounds. Related to both, another goal is to develop a training curriculum that makes learning to interpret the sounds and use the device in daily life as easy as possible. The broader impact of this research is the rehabilitation of the blind, enabling them to interact with their environment in ways that are otherwise impossible - recognizing and localizing objects at a distance, and being able to navigate in an environment without touching or bumping in to things. It is anticipated that the device can enhance the personal freedom and independence of the blind, enabling them to engage in a larger spectrum of activities, and empowering their integration and interaction with the rest of society.
Windy Hill Medical is a medical device and pharmaceutical company focused on the development of products to reduce the risk of developing breast cancer in patients deemed to be at high risk.